TobiasWalbertMD

Neurology • Detroit, MI

Neurooncology, Hospice and Palliative Medicine

Associate Professor, Neurology, Wayne State University SOM

Join to view full profile

Dr. Walbert is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Walbert's full profile

Already have an account?

Office
2799 W. Grand Boulevard
Detroit, MI 48202
Phone+1 313-916-2723

Education & Training

University of Texas M D Anderson Cancer CenterFellowship, Neuro-Oncology, 2008 - 2010
Case Western Reserve University/University Hospitals Cleveland Medical CenterResidency, Neurology, 2005 - 2008
Case Western Reserve University/University Hospitals Cleveland Medical CenterInternship, Internal Medicine, 2004 - 2005
OtherClass of 2000

Certifications & Licensure

FL State Medical License 2021 - Present
MI State Medical License 2009 - 2026
OH State Medical License 2004 - 2008
American Board of Internal Medicine Hospice and Palliative Medicine
American Board of Psychiatry and Neurology Neurology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM) Start of enrollment: 2009 Jun 01
Completed
Phase 3
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma Start of enrollment: 2015 Nov 30
Terminated
Phase 2, Phase 3
Terameprocol in Treating Patients With Recurrent High Grade Glioma Start of enrollment: 2018 May 03
Completed
Phase 1
Study of the Effect NT-I7 on CD4 Counts in Patients With High Grade Gliomas Start of enrollment: 2018 Oct 30
Terminated
Phase 1
Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer Start of enrollment: 2018 Jul 09
Recruiting
Phase 1
Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Start of enrollment: 2017 Jun 07
Terminated
Phase 1
MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas Start of enrollment: 2019 Sep 29
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

37 citations
Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial.
Macarena I de la Fuente, Howard Colman, Mark Rosenthal, Brian A Van Tine, Danijela Levacic
Neuro-Oncology. 2023-01-05
12 citations
Palliative Care, End-of-Life Care, and Advance Care Planning in Neuro-oncology
Tobias Walbert
Continuum. 2017-12-01
52 citations
SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors.
Tobias Walbert, Rebecca Harrison, David Schiff, Edward K. Avila, Merry Chen
Neuro-Oncology. 2021-11-02

Press Mentions

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Looking to Fill Glioblastoma Multiforme Treatment Gap with Berubicin Drug ProductAugust 30th, 2022
Henry Ford Health Researchers Launch Clinical Trial Studying Therapy Aimed at Causing Brain Cancer Cells to Self-DestructJune 10th, 2023